Anorexic agents

Reaction of the Grignard reagent prepared from m-trifluoromethylbromobenzene (37) with methyl-1, 2 -dibromoethylether leads to alkoxy bromide 38, which is then reacted with methylamine to give the anorexic agent fludo7-ex (39). 

Amphetamines and anorexic agents These drugs have potential for causing dependence, hypertension, angina, and myocardial infarction. High... 

There have been a number of medical explorations. Under the code SKF-5 (and trade name of Amphedoxamine) it was explored as an anorexic agent. It has been found promising in the treatment of psychoneurotic depression. There are several medical reports, and one book (Claudio Naranjo s The Healing Journey), that describe its values in psychotherapy. 

Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1996 94(9) 2216-20. 

In 1996, in a case-control study, 95 patients from 35 centers in France, Belgium, the UK, and the Netherlands were compared with 355 age- and sex-matched controls (14). The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension. Association with recognized risk factors such as a family history of primary pulmonary hypertension, infection with HIV, or the use of intravenous drugs was also confirmed. The absolute risk for obese patients who took anorexic agents for more than 3 months was 30 times higher than in non-users. 

The factors leading to the development of pulmonary hypertension are unclear, although associations with portal hypertension and pregnancy have been detected. Obesity by itself may double the risk of pulmonary hypertension. Additionally, the use of cocaine or oral contraceptives, infection with the human immunodeficiency virus (HIV), the use of anorexic agents, hepatic cirrhosis, genetic susceptibility, and female sex in the third to fourth decades of life also have been implicated as predisposing factors. Exposure of patients to fenfluramine or dexfenfluramine has been associated with 20% of all diagnosed cases of pulmonary hypertension. ... 

In September 1997, the FDA requested the manufacturers of fenfluramine and dexfenfluramine to voluntarily withdraw their products from the market. This was done following case reports of valvular heart disease in patients taking either medication as monotherapy or in combination with another anorexic agent, phentermine. Because no association has been found between phentermine alone and valvular heart disease, it is still available. Isolated case reports of pulmonary hypertension and phentermine monotherapy have been reported, but present data do not support an association. Although fenfluramine and phentermine were both approved by the FDA to be used as anorectic agents, the combination therapy, fen-phen, was never approved. 

Anorexic agents—These drugs are appetite suppressants which are used as part of the treatment for obesity, augmenting the other part of the treatment consisting of a nutritious, calorie-restricted diet. 

Succinate [5634-40-2]. Levamfetamine succinate, USAN. Amodril. Cydril. Miagret Anorexic agent. 

---